Atara Biotherapeutics Inc. (NASDAQ:ATRA) rose 7.2% during mid-day trading on Monday . The company traded as high as $22.83 and last traded at $22.75, with a volume of 61,960 shares. The stock had previously closed at $21.22.

ATRA has been the subject of a number of research reports. Jefferies Group reaffirmed a “buy” rating and set a $22.00 target price (down previously from $26.00) on shares of Atara Biotherapeutics in a report on Monday, May 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $47.00 target price on shares of Atara Biotherapeutics in a report on Friday, May 6th. Zacks Investment Research lowered shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 10th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $27.71.

The stock’s market capitalization is $656.31 million. The stock’s 50 day moving average price is $22.66 and its 200 day moving average price is $19.25.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.05. On average, equities research analysts expect that Atara Biotherapeutics Inc. will post ($2.75) EPS for the current fiscal year.

In other Atara Biotherapeutics news, COO Gad Soffer sold 5,427 shares of the firm’s stock in a transaction on Tuesday, May 17th. The stock was sold at an average price of $15.91, for a total value of $86,343.57. Following the completion of the sale, the chief operating officer now owns 138,125 shares of the company’s stock, valued at $2,197,568.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Isaac E. Ciechanover sold 12,000 shares of the firm’s stock in a transaction on Wednesday, June 8th. The shares were sold at an average price of $20.53, for a total value of $246,360.00. Following the completion of the sale, the chief executive officer now directly owns 223,228 shares of the company’s stock, valued at approximately $4,582,870.84. The disclosure for this sale can be found here.

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.